

MannKind to enter deal with Cipla for Afrezza in India

10 May 2018 | News

Under the terms of the agreement, Cipla will be responsible for obtaining regulatory approvals and marketing, while MannKind is responsible for supply.



MannKind Corporation announced an exclusive marketing and distribution agreement for Afrezza in India with Cipla Ltd., a global pharmaceutical company. MannKind Corporation is a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.

Afrezza is the only United States Food and Drug Administration (USFDA) approved inhaled insulin available for patients suffering from diabetes.

Under the terms of the agreement, Cipla will be responsible for obtaining regulatory approvals to distribute Afrezza in India, including approval from the Drug Controller General of India (DCGI).

Cipla will also be responsible for all marketing and sales activities of Afrezza in India. MannKind is responsible for supplying Afrezza to Cipla.